HOECHST FLOATS $7.2 BIL. OFFER FOR MARION MERRELL DOW: FROM MMD'S PERSPECTIVE, DEAL COULD TRADE ONE CHEMICAL PARENT FOR ANOTHER; COPLEY WOULD JOIN WITH RUGBY
Hoechst's $7.2 bil. offer for Marion Merrell Dow would be worth over $5.1 bil. to Dow but does not appear to offer a significant premium either to Dow's five-year investment in the company or to the current trading price of the 29% of the stock not owned by Dow.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth